Covered recipient · General Payments record
CIMBERLY FAYE BERG
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$1,518.03
- Reported across 75 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $524.11 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $269.64 | 19 |
| Astellas Pharma US Inc | $65.94 | 3 |
| PFIZER INC. | $42.73 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.28 | 1 |
| Lilly USA, LLC | $21.10 | 1 |
| Novo Nordisk AS | $20.29 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.63 | 1 |
| Amgen Inc. | $17.36 | 1 |
| Exact Sciences Corporation | $17.28 | 1 |
| Otsuka America Pharmaceutical, Inc. | $15.16 | 1 |
| Acerta Pharma LLC | $14.70 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.91 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516750 | CMS |
| ABBVIE INC. | $14.61 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516752 | CMS |
| ABBVIE INC. | $13.73 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516754 | CMS |
| ABBVIE INC. | $9.76 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516756 | CMS |
| ABBVIE INC. | $12.81 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516758 | CMS |
| ABBVIE INC. | $18.85 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516760 | CMS |
| ABBVIE INC. | $15.25 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516762 | CMS |
| ABBVIE INC. | $7.39 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516764 | CMS |
| ABBVIE INC. | $16.76 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516766 | CMS |
| ABBVIE INC. | $16.33 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516768 | CMS |
| ABBVIE INC. | $17.61 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516770 | CMS |
| ABBVIE INC. | $8.54 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516772 | CMS |
| ABBVIE INC. | $20.18 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516774 | CMS |
| ABBVIE INC. | $3.40 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516776 | CMS |
| ABBVIE INC. | $16.59 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516778 | CMS |
| ABBVIE INC. | $10.12 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516780 | CMS |
| ABBVIE INC. | $14.32 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516782 | CMS |
| ABBVIE INC. | $21.97 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516784 | CMS |
| ABBVIE INC. | $12.51 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106516786 | CMS |
| Amgen Inc. | $17.36 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115447790 | CMS |
| Astellas Pharma US Inc | $19.92 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139500718 | CMS |
| Astellas Pharma US Inc | $25.10 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139501102 | CMS |
| Astellas Pharma US Inc | $20.92 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139533180 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.70 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105575836 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $18.63 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086342101 | CMS |
| Exact Sciences Corporation | $17.28 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114590532 | CMS |
| Lilly USA, LLC | $21.10 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135557706 | CMS |
| Novo Nordisk Inc | $20.29 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100436365 | CMS |
| Otsuka America Pharmaceutical, Inc. | $15.16 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119026084 | CMS |
| PFIZER INC. | $14.33 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131583700 | CMS |
| PFIZER INC. | $14.75 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131563398 | CMS |
| PFIZER INC. | $13.65 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131525713 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.28 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137713335 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.